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This paper deals with the scientometric analysis of the global literature on 
Hydroxychloroquine as indexed in SCOPUS database from its first publication in 1946 to 2020. The 
objective of the study was to perform a scientometric analysis of Hydroxychloroquine publications. 
The study analyzed 25,163 publications which were contributed by 88,834 individual authors 
affiliated to 159 countries. The results showed momentum in the research publications during the 
1980s and accelerated immediately from the beginning of the 21st century. It was observed a 
fluctuating trend for the Annual Growth Rate and CAGR recorded to 0.129635. The Relative Growth 
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Rate recorded between 0.04 and 0.56 for different years. The Degree of Collaboration (DC) noted 
was 0.88 and 5.27 Collaboration Index (CI). The Journal of Rheumatology was the most preferred 
journal with 864 publications; Didier A. Raoult was the most productive author in 
Hydroxychloroquine (HCQ) research. The AP-HP Assistance Publique - Hopitaux de Paris, France 
was the top productive institution globally, and the USA was the most productive country in terms of 
the number of publications.  
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The recent pandemic Coronavirus disease (COVID-19) posed a severe threat to public health 
globally and risked people's lives due to the initial lack of drug or vaccine to treat it. The World 
Health Organization's report on COVID-19 Situation Dashboard (2020) stated that COVID-19 
affected more than 219 countries and territories. More than ten crores of people got infected, and 
more than 22 lack people have dead (as on 2nd of February 2021). Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), is the cause of coronavirus disease-2019 (COVID-19) started from 
Wuhan, China, on 31 December 2019. The rapid increase of Coronavirus disease led to an outbreak 
with high mortality and morbidity (Lai et al., 2020). The World Health Organization named the novel 
coronavirus disease as COVID-19 on February 11, 2020. COVID-19 is similar to Severe Acute 
Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MARS) that can cause fever 
and severe respiratory symptoms, such as cough, wheezing, and dyspnea (Chan et al., 2020; Huang et 
al., 2020; and Wu et al. 2020). Many countries announced the total lock-down, which ceases the 
complete human activities. Due to the impact of COVID-19, there was a substantial economic loss to 
the governments and private organisations and affected the operations in all spheres, including health 
care and public work activities. In some countries, scientists worked 24*7 to determine the drug or 
vaccine to treat the COVID-19 affected people.  
 
 Moreover, "Vaccine development is a long, complex process, often lasting 10-15 years and 
involving a combination of public and private involvement" (History of Vaccines, 2018). Hence, 
many Research and Development (R & D) organizations and drug control authorities stressing upon 
'Drug Repurposing'. Drug Repurposing is also known as drug repositioning, a strategy to use existing 
approved drugs to new diseases. Drug Repurposing will reduce time, cost and human labour involved 
in new drug development and production. With such efforts, the World Health Organization (2020) 
announced "Solidarity" clinical trial for COVID-19 treatments using clinical drug repurposing for 
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various drugs like Remdesivir, Lopinavir / Ritonavir, Chloroquine and Hydroxychloroquine. The 
Chloroquine and Hydroxychloroquine are closely related and used to treat Rheumatology conditions 
and Malaria, respectively. Hydroxychloroquine was used for many decades to treat Malaria and 
autoimmune diseases like rheumatoid arthritis and Lupus. 
 
What is Hydroxychloroquine?  
 
 Quinoline based molecules have long been used for the treatment of Malaria, beginning with 
quinine. The chemical modifications of quinine led to more potent and inexpensive Aminoquinoline 
(AQ) drug molecules such as Chloroquine (CQ) and Hydroxychloroquine (HCQ) etc. The most 
widespread disease in the world is Malaria. World Health Organization (WHO) has estimated around 
40% world population presently lives under malaria threats, and annually Malaria occurs 
approximately 300–500 million cases, leading to 1–3 million deaths. Mainly, mortality is higher in 
children below the age of 5 years and statistics reveals that about 25% of child deaths are found in 
Africa (Chew et al. 2019; Marmor et al. 2011; and Wang et al. 2017). In this line, CQ generally used 
for the treatment of malarial infections, followed by HCQ. The entire world has witnessed a COVID-
19 pandemic, due to which, there is a sudden increase in the interest of antimalarial and anti-
inflammatory drug molecules, more particularly Hydroxychloroquine.  
 
 Hydroxychloroquine (Plaquenil) is also considered a Disease-Modifying Anti-Rheumatic 
Drug (DMARD). It can reduce the pain and swelling of arthritis. It may prevent joint damage and 
reduce the risk of long-term disability. Earlier the Hydroxychloroquine was used intensively to treat 
Malaria across the world. Presently, HCQ is also used to treat childhood arthritis, some lupus 
symptoms, rheumatoid arthritis and other autoimmune diseases. It is believed that 
Hydroxychloroquine interferes with the communication of cells in the immune system (American 
College of Rheumatology). This may be one of the reasons why HCQ is used effectively in treating 
autoimmune diseases. Hydroxychloroquine is very similar to Chloroquine. However, it has lesser side 
effects, but one of the best known antimalarial drugs. According to Das (2020), HCQ has some 
antiviral properties because it was selectively used in coronavirus treatment.   
 
  
Review of Related Literature 
 
 The authors have made an effort to present the review of literature in two parts. In the first 
part, the papers pertaining to the treatment, therapeutic drugs, antiviral vaccines and traditional 
clinical results are highlighted. The latter part deals with the literature on Scientometric analysis. The 
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Coronavirus pandemic has posed many challenges to all the nations (both developed and developing), 
be it economic, socio-cultural activities, etc. Due to which people's lives have badly affected. On the 
other hand, it has triggered an avalanche of scientific research, both within and outside the medical 
domain, to help communities, overcome this challenge by minimising its adverse impacts (Haghani et 
al.).  
The plethora of scientists, pharma companies are trying to find out the vaccine for this 
pandemic. Many traditional clinical practice results across the world playing a significant role in the 
treatment of COVID-19 but efficacy and safety remain unclear.  
 
In their paper, Ren et al. (2020) discuss that the traditional clinical practices/medicines play a 
significant role in the treatment of COVID-19. Early intervention, especially Traditional Chinese 
Medicines (TCM), can effectively prevent the COVID-19 from transforming into severe disease. 
However, Gray and Belessis (2020) report that the benefits of TCM in the treatment of Corona Virus 
disease remain unproven and injurious to health. On the other hand, a Chinese team published results 
of a study demonstrating that Chloroquine, an antimalarial, and its hydroxyl analogue, 
Hydroxychloroquine inhibit SARS-CoV- 2 in vitro with EC50 = 0.72%μM found to be more potent 
than Chloroquine (EC50 = 5.47%μM) (Yao et al., 2020). In support of this, a French paper reveals 
that Hydroxychloroquine with azithromycin is more effective in treating COVID-19 patients (Gautret 
et al., 2020).   
 
 The Hydroxychloroquine (HCQ) drug has been initially used to treat Malaria, since it may 
inhibit the plasmodial heme polymerase. However, several clinical observations and experiments have 
also proved that it is an effective drug for various diseases, including Dyslipidemias, Coagulopathies, 
Diabetes Mellitus, Malignancies and Autoimmune diseases Systematic Lupus Erythematosus (SLE), 
Rheumatoid Arthritis and Sjogren's Syndrome (Olsen et al., 2013). Considering that there is no 
alternative and better option presently, HCQ is regarded as god sent the drug to treat COVID-19. 
Large-scale basic and clinical research is still needed to clarify its specific mechanism (Chen et al., 
2020). The available data show that the use of HCQ in patients with SLE is effective and safe. HCQ 
can be used to treat constitutional symptoms of Lupus, such as joint pain and swelling, rashes, and 
fatigue. However, the drug may also be given along with steroids and immunosuppressive drugs to 
improve the life expectancy of patients with SLE and in reducing lupus flares and organ damage 
accrual (Ponticelli and Moroni, 2017). Another study conducted by Srivastava et al. (2020) reveal that 
the application of graphene-based materials for combating SARS-CoV-2 virus and associated 
COVID-19, their outstanding physicochemical and antimicrobial properties suggest that these 
materials may play a crucial role on various fronts in the war against COVID-19. Ultimately, 




 The published literature reveals that very few Scientometric studies have been conducted on 
various vaccines to treat fever, Malaria, Artemisia, Plasmodium vivax and Coronavirus disease. Garg 
et al. (2009) conducted a bibliometric analysis of global malaria vaccine research based on the 
publication records extracted from PubMed databases during 1972-2004. A total of 2007 publication 
records were analysed, which published in 352 journals from 40 different countries. 37.2% of malaria 
vaccine research was published by the USA, followed by the United Kingdom. The National Institutes 
of Health (USA) and the Naval Medical Research Institute (USA) were the most prolific institutes. 
Infection and Immunity was the most preferred journal, followed by Vaccine.  
 
 Ram (2011) conducted a bibliometric study to analyse the research publications on 
"Artemisia" which is a herb used to treat Malaria. The study examined 1484 research publications 
indexed in the PubMed database for the period from 1996 to 2010. The author observed a consistent 
growth of literature year by year. China contributed maximum, i.e. 24% of the total publications, 
followed by the USA (16%). The Journal of Ethnopharmacology was the most preferred journal, 
followed by Planta Medica. The study further analysed India's contribution to Artemisia research. A 
total of 214 Indian authors contributed in 56 publications.  
 
 Yao et al. (2012) attempted to analyse publications on Artemisia annua, which is Chinese 
traditional medicine to treat fever and Malaria. A total of 4076 Publications were extracted from the 
Science Citation Index (SCI), and 4065 publications data were extracted from Medline till December 
2011. The research outputs were considered for the study to evaluate the global scientific production 
and developing trend of artemisinin research. The study found that the research on Artemisia annua 
started in 1980 but boosted only after 2000. Though Artemisia annua is Chinese traditional medicine, 
the highest number of research papers were published by the scientists affiliated to the USA, followed 
by the UK. The Chinese Academy of Sciences and Thailand Mahidol University published a 
maximum number of research papers. Fu et al. (2015) conducted a bibliometric analysis of malaria 
research in China. They have retrieved Five thousand one hundred twenty-six records from China 
National Knowledge Infrastructure (CNKI), Wanfang database, Cqvip and PubMed from 2004 to 
2014. The study found that 2013 was the most productive year. China Centers for Disease Control and 
Prevention (CDC) was the most productive institute, and China Tropical Medicine was the most 
preferred journal to publish malaria research.  
 
 Garrido-Cardenas et al. (2019) analysed the global research on Malaria and Plasmodium 
vivax extracted from Scopus database with 11,166 documents published between 1916 and 2018. The 
analysis showed that the year 2012 was the most productive year with the highest number of 
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publications. The United States of America, United Kingdom and India were the most productive 
countries in Malaria and Plasmodium vivax. Mahidol University and the University of Oxford were 
the most productive institutes during the period of study. Whereas, Tran et al. (2019) analysed 
HIV/AIDS and economic evaluation articles published between 1990 and 2017 as indexed in the Web 
of Science database. There were 2,50,270 publications indexed on HIV/AIDS; 372 publications were 
on economic evaluations in HIV/AIDS.  However, this study analysed 372 research publications and 
found that 2013 was the most productive year and publications in the year 2001 received the highest 
number of citations. Overall, 46 countries contributed, and out of which the USA and the UK 
contributed the highest number of publications. 
 
 Singh and Mahanty (2019) conducted a bibliometric study of research trends on Malaria in 
India. A total of 2,334 publications covered in Web of Science during 1909 and March 2019 were 
considered for the study. The first prominent peak in the malaria research in India was noticed during 
1991. From 2002 to 2013 increasing trend was noticed, with the highest rise in 2016 and a continuous 
downfall was noticed afterwards. The most preferred collaborating country was the USA, followed by 
the UK. The Journal of Vector-Borne Diseases was the most preferred journal by the researchers. 
Malaria and India were the most preferred keywords. Academic institutions followed by research 
institutions are the major contributors to the output of malaria research. Most of the highly productive 
institutions are located in the USA and the UK. 
 
Shettar and Hadagali (2020) analysed world research publications on Coronavirus indexed in 
the Scopus database from 1951 to 2019. A total of 18,116 publication records were analysed which 
published in 2,562 journals from 150 different countries. The study found the Journal of Virology was 
a most preferred journal with 6.55% articles of overall publications. Luis Enjuanes from Centro 
Nacional de Biotecnologia Consejo Superior de Investigaciones Cientificas (CNB, CSIC), Spain was 
the leading author; the University of Hong Kong was the leading institution in the field Coronavirus 
research. The USA has contributed 31.22% of the overall publication. 
 
 Lou et al. (2020) analysed the publications on COVID-19 to provide references to recent 
publications of 183 publications till 1st March 2020. The study was based on the records retrieved 
from the PubMed database. The study found that corresponding authors of these publications were 
from 20 different countries, and 78 corresponding authors worked in hospitals. Out of 183 
corresponding authors, 123 were from China, followed by the USA (18). The Journal of Medical 




  From the above review, no single study was conducted on the scientometric analysis of the 
literature on Hydroxychloroquine, and this research would try to bridge the gap.  
 
Objectives of the Study  
 
 The present study's main objective is to identify and analyse the global publications' 
productivity in the field of Hydroxychloroquine from 1946 to 2020. The specific objectives are to: 
 
1. study the publications pattern in the field of Hydroxychloroquine;  
2. determine the Annual Growth Rate (AGR), Relative Growth Rate (RGR) and Doubling Time 
(Dt.) in the field of Hydroxychloroquine;  
3. analyse the Degree of Collaboration (DC), Collaborative Coefficient (CC) and Collaboration 
Index (CI);  
4. study the top twenty-five most productive journals, fruitful authors, prolific institutions and 
countries; and  
5. identify the top five highly cited papers in the field of Hydroxychloroquine.  
 
Materials and Methods used 
 
 For this study, the data were collected from the Elsevier Scopus database for the period from 
1946 to 2020. A total of 25,163 bibliographic records indexed in the Scopus database were retrieved 
in the CSV (comma-separated values) file format and further analysed using MS-Excel and online 
tools. The search syntax was used to retrieve the data from Scopus as TITLE-ABS-KEY 
(Hydroxychloroquine). The mathematical formulae were used to compute the records using various 
parameters on Hydroxychloroquine. 
 
ANALYSIS AND INTERPRETATION OF DATA 
 
Year-wise distribution of publications 
 
 Table 1 depicts the year-wise distribution of publications on Hydroxychloroquine, and figure 
1 presents the Annual Growth of publications and citations. The first publication on 
Hydroxychloroquine (in Scopus database) was found in the year 1946. A total of 25,163 publications 
were published from 1946 to 2020 and received a total of 5,67,632 citations. Up to 1961, there was 
less number of publications (with single-digit). The highest numbers of publications, i.e. 5,736 were 
published during 2020, followed by 1,361 (in 2019) and 1,281 (in 2018). The highest numbers of 
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citations were received for publications of the year 2020 (52,753) followed by publications in 2006 
(32,840 citations) and 2009 (32,496 citations). The overall average citations per paper (ACPP) 
recorded for the period of the study is 22.56 and highest ACPP of 49.93 recorded for the publications 
in the year 2003 followed by 2005 (48.07 ACPP) and 2006 (44.74 ACPP).  
 
Table 1: Year-wise distribution of publications 









1946 1 1 1.00 1985 116 3531 30.44 
1948 2 3 1.50 1986 111 1906 17.17 
1949 1 1 1.00 1987 78 1840 23.59 
1952 1 4 4.00 1988 93 2228 23.96 
1953 1 0 0.00 1989 96 1741 18.14 
1954 1 6 6.00 1990 117 2851 24.37 
1955 2 9 4.50 1991 178 4697 26.39 
1956 2 17 8.50 1992 197 4998 25.37 
1957 2 14 7.00 1993 256 6107 23.86 
1958 2 24 12.00 1994 259 7391 28.54 
1959 2 56 28.00 1995 278 8131 29.25 
1960 4 21 5.25 1996 262 9496 36.24 
1961 2 12 6.00 1997 204 7090 34.75 
1962 16 110 6.88 1998 243 5369 22.09 
1963 29 697 24.03 1999 287 9460 32.96 
1964 22 54 2.45 2000 305 10292 33.74 
1965 22 214 9.73 2001 350 13886 39.67 
1966 15 291 19.40 2002 460 19835 43.12 
1967 16 269 16.81 2003 500 24964 49.93 
1968 10 204 20.40 2004 571 21376 37.44 
1969 9 149 16.56 2005 644 30960 48.07 
1970 14 149 10.64 2006 734 32840 44.74 
1971 16 251 15.69 2007 798 30621 38.37 
1972 7 26 3.71 2008 847 28388 33.52 
1973 40 313 7.83 2009 884 32496 36.76 
1974 35 673 19.23 2010 884 31144 35.23 
1975 52 679 13.06 2011 870 27978 32.16 
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1976 50 683 13.66 2012 961 26169 27.23 
1977 62 721 11.63 2013 1056 23948 22.68 
1978 55 518 9.42 2014 926 19705 21.28 
1979 69 1250 18.12 2015 970 17947 18.50 
1980 84 1184 14.10 2016 1052 15489 14.72 
1981 73 722 9.89 2017 1198 13639 11.38 
1982 108 1735 16.06 2018 1281 10056 7.85 
1983 101 2171 21.50 2019 1361 6310 4.64 
1984 95 1641 17.27 2020 5736 52753 9.20 
Total 25163 567632 22.56 
ACPP: Average Citation per Publication 
 
 
Fig. 1: Annual growth rate of publications and citations 
(TP: Total Publications; TC=Total Citations) 
 
 
Annual Growth Rate (AGR) of publications 
 
The Annual Growth Rate (AGR) is calculated on the formula given by Gracio et al. (2013). 
AGR is a simple and standard for measuring the growth in a particular year using only two 
parameters, i.e. First Value and End Value. According to Choi et al. (2011), the Growth rate is being 
measured with Compound Growth Rate (CAGR). CAGR is a standard for measuring the growth for 
the overall period of study. Table 2 presents the annual growth rate (AGR) and Compound Annual 
Growth Rate (CAGR). There was a fluctuating trend observed for AGR throughout the study period. 
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The maximum AGR, i.e. 700 was recorded for 1962, followed by 471.43 during 1973 and 321.45 
recently in the year 2020. While the minimum AGR was recorded, i.e. -56.25 for the year 1972. The 
Compound Annual Growth Rate (CAGR) for the total period has arrived at 0.129635. 
 
Table 2: Annual Growth Rate (AGR) of publications 
Year  Total 
Publications  AGR 
Year  Total 
Publications AGR 
1946 1 0.00 1985 116 22.11 
1948 2 100.00 1986 111 -4.31 
1949 1 -50.00 1987 78 -29.73 
1952 1 0.00 1988 93 19.23 
1953 1 0.00 1989 96 3.23 
1954 1 0.00 1990 117 21.88 
1955 2 100.00 1991 178 52.14 
1956 2 0.00 1992 197 10.67 
1957 2 0.00 1993 256 29.95 
1958 2 0.00 1994 259 1.17 
1959 2 0.00 1995 278 7.34 
1960 4 100.00 1996 262 -5.76 
1961 2 -50.00 1997 204 -22.14 
1962 16 700.00 1998 243 19.12 
1963 29 81.25 1999 287 18.11 
1964 22 -24.14 2000 305 6.27 
1965 22 0.00 2001 350 14.75 
1966 15 -31.82 2002 460 31.43 
1967 16 6.67 2003 500 8.70 
1968 10 -37.50 2004 571 14.20 
1969 9 -10.00 2005 644 12.78 
1970 14 55.56 2006 734 13.98 
1971 16 14.29 2007 798 8.72 
1972 7 -56.25 2008 847 6.14 
1973 40 471.43 2009 884 4.37 
1974 35 -12.50 2010 884 0.00 
1975 52 48.57 2011 870 -1.58 
1976 50 -3.85 2012 961 10.46 
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1977 62 24.00 2013 1056 9.89 
1978 55 -11.29 2014 926 -12.31 
1979 69 25.45 2015 970 4.75 
1980 84 21.74 2016 1052 8.45 
1981 73 -13.10 2017 1198 13.88 
1982 108 47.95 2018 1281 6.93 
1983 101 -6.48 2019 1361 6.25 
1984 95 -5.94 2020 5736 321.45 
CAGR (1946-2020) 0.129635 
(AGR: Annual Growth Rate and CAGR: Compound Annual Growth Rate) 
 
 
Relative Growth Rate (RGR) and Doubling Time (Dt.) of publications 
 
 The Relative Growth Rate (RGR) increases the number of articles/pages per unit of time. This 
definition is derived from the definition of relative growth rates in the study of growth analysis of 
individual plants and is effectively applied in the field of botany (Hunt, 1978 & 1982; Poorter & 
Garnier, 1996; Hoffmann & Poorter, 2002). Doubling time (Dt.) is defined as the time to be taken to 
double in the size or value and exists a direct equivalence between the relative growth rate and the 
doubling time. The Doubling time can be calculated by dividing the natural logarithm of 2 by the 
RGR calculated for the time period. Doubling time (Dt.) is calculated on the formula suggested by 
Mahapatra (1985). It is observed from Table 3 that the value of Relative Growth Rate (RGR) 
decreased from 0.55 in 1948 to 0.25 in 2020. The fluctuating trend was observed throughout the study 
period. The values of Doubling Time (Dt.) of publications increased from 1.26 in 1948 to 19.35 
during 1972 again decreased to 10.19 during 2019, recently in 2020 it is recorded at 2.80. A 
fluctuation trend was observed in Dt during the study period. Figure 2 presents the data on year-wise 
Relative Growth Rate (RGR) and Doubling Time (Dt.).  
 






Publications W1 W2 RGR Dt 
1946 1 1 0.00 0.00 0.00 0.00 
1948 2 3 0.00 1.10 0.55 1.26 
1949 1 4 1.10 1.39 0.29 2.41 
1952 1 5 1.39 1.61 0.07 9.32 
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1953 1 6 1.61 1.79 0.18 3.80 
1954 1 7 1.79 1.95 0.15 4.50 
1955 2 9 1.95 2.20 0.25 2.76 
1956 2 11 2.20 2.40 0.20 3.45 
1957 2 13 2.40 2.56 0.17 4.15 
1958 2 15 2.56 2.71 0.14 4.84 
1959 2 17 2.71 2.83 0.13 5.54 
1960 4 21 2.83 3.04 0.21 3.28 
1961 2 23 3.04 3.14 0.09 7.62 
1962 16 39 3.14 3.66 0.53 1.31 
1963 29 68 3.66 4.22 0.56 1.25 
1964 22 90 4.22 4.50 0.28 2.47 
1965 22 112 4.50 4.72 0.22 3.17 
1966 15 127 4.72 4.84 0.13 5.51 
1967 16 143 4.84 4.96 0.12 5.84 
1968 10 153 4.96 5.03 0.07 10.25 
1969 9 162 5.03 5.09 0.06 12.12 
1970 14 176 5.09 5.17 0.08 8.36 
1971 16 192 5.17 5.26 0.09 7.96 
1972 7 199 5.26 5.29 0.04 19.35 
1973 40 239 5.29 5.48 0.18 3.78 
1974 35 274 5.48 5.61 0.14 5.07 
1975 52 326 5.61 5.79 0.17 3.99 
1976 50 376 5.79 5.93 0.14 4.86 
1977 62 438 5.93 6.08 0.15 4.54 
1978 55 493 6.08 6.20 0.12 5.86 
1979 69 562 6.20 6.33 0.13 5.29 
1980 84 646 6.33 6.47 0.14 4.97 
1981 73 719 6.47 6.58 0.11 6.47 
1982 108 827 6.58 6.72 0.14 4.95 
1983 101 928 6.72 6.83 0.12 6.01 
1984 95 1023 6.83 6.93 0.10 7.11 
1985 116 1139 6.93 7.04 0.11 6.45 
1986 111 1250 7.04 7.13 0.09 7.45 
1987 78 1328 7.13 7.19 0.06 11.45 
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1988 93 1421 7.19 7.26 0.07 10.24 
1989 96 1517 7.26 7.32 0.07 10.60 
1990 117 1634 7.32 7.40 0.07 9.33 
1991 178 1812 7.40 7.50 0.10 6.70 
1992 197 2009 7.50 7.61 0.10 6.71 
1993 256 2265 7.61 7.73 0.12 5.78 
1994 259 2524 7.73 7.83 0.11 6.40 
1995 278 2802 7.83 7.94 0.10 6.63 
1996 262 3064 7.94 8.03 0.09 7.75 
1997 204 3268 8.03 8.09 0.06 10.75 
1998 243 3511 8.09 8.16 0.07 9.66 
1999 287 3798 8.16 8.24 0.08 8.82 
2000 305 4103 8.24 8.32 0.08 8.97 
2001 350 4453 8.32 8.40 0.08 8.47 
2002 460 4913 8.40 8.50 0.10 7.05 
2003 500 5413 8.50 8.60 0.10 7.15 
2004 571 5984 8.60 8.70 0.10 6.91 
2005 644 6628 8.70 8.80 0.10 6.78 
2006 734 7362 8.80 8.90 0.11 6.60 
2007 798 8160 8.90 9.01 0.10 6.73 
2008 847 9007 9.01 9.11 0.10 7.02 
2009 884 9891 9.11 9.20 0.09 7.40 
2010 884 10775 9.20 9.28 0.09 8.10 
2011 870 11645 9.28 9.36 0.08 8.92 
2012 961 12606 9.36 9.44 0.08 8.74 
2013 1056 13662 9.44 9.52 0.08 8.61 
2014 926 14588 9.52 9.59 0.07 10.57 
2015 970 15558 9.59 9.65 0.06 10.76 
2016 1052 16610 9.65 9.72 0.07 10.59 
2017 1198 17808 9.72 9.79 0.07 9.95 
2018 1281 19089 9.79 9.86 0.07 9.98 
2019 1361 20450 9.86 9.93 0.07 10.06 







Fig. 2: Year-wise Relative Growth Rate and Doubling Time 
(RGR=Relative Growth Rate; Dt.=Doubling Time) 
 
 
Degree of Collaboration (DC) 
 
 The Degree of Collaboration in different years was calculated as per the mathematical 
formula proposed by Subramanyam (1983) based on two parameters in publications, i.e. Single 
authored papers, and Multi-authored papers. Table 4 presents the block year-wise Degree of 
Collaboration (DC) in the field of Hydroxychloroquine. The block period 1946-1950 witnessed the 
lowest DC, i.e. 0.50 (2 out of 4 publications) single-authored papers and the block period 2016-2020 
has recorded DC of 0.94 with the highest (9915) multi-authored papers. The Degree of Collaboration 
(DC) varied from 0.50 to 0.94 throughout the study period. The mean value of DC throughout the 
study period was 0.88. The block periods from 2001-05, 2006-10, 2011-2015 and 2016-2020 have 
more than 0.8 DC. The block period 2016-2020 has seen the highest (0.94) DC.   
 
Table 4: Degree of Collaboration (DC): Block wise 
Publication Years 
(5 Years Block) 












(Ns + Nm) 
Degree of 
Collaboration 
1946-50 0 0.00 2 0.06 2 0.01 4 0.50 
1951-55 0 0.00 2 0.06 3 0.01 5 0.60 
1956-60 0 0.00 4 0.13 8 0.04 12 0.67 
15 
 
1961-65 1 0.47 35 1.12 55 0.24 90 0.61 
1966-70 1 0.47 19 0.61 44 0.19 63 0.70 
1971-75 3 1.42 50 1.60 97 0.42 147 0.66 
1976-80 3 1.42 137 4.37 180 0.79 317 0.57 
1981-85 11 5.19 187 5.97 295 1.29 482 0.61 
1986-90 11 5.19 147 4.69 337 1.48 484 0.70 
1991-95 27 12.74 280 8.93 861 3.77 1141 0.75 
1996-2000 21 9.91 309 9.86 971 4.25 1280 0.76 
2001-05 42 19.81 433 13.82 2050 8.98 2483 0.83 
2006-10 21 9.91 519 16.56 3607 15.79 4126 0.87 
2011-15 20 9.43 348 11.10 4415 19.33 4763 0.93 
2016-20 51 24.06 662 21.12 9915 43.41 10577 0.94 




Collaborative Coefficient (CC) and Collaboration Index (CI) 
 
 The table 5 shows that multi-authored publications (87.23%) dominate over the single-
authored publications (11.97%). There were a few research papers with anonymous authors (0.81%). 
The authorship pattern shows that the number of publications by mega-authored (five and above) 
papers dominated with 11,196 (42.76%) publications, followed by two authored papers with 4,284 
(16.36%) publications and three authored papers with 3,898 (14.89%) publications. Collaboration 
Coefficient (CC) as defined by Ajiferuke et al. (1988) lies between 0 and 1, with 0 correspondings to 
single-authored papers. The CC during the study ranges between 0, and 0.80, with an average, are 
0.63. If the CC's value is more than 0.5, then the collaboration rate among the authors is found better. 
Up to 1991 except 4 years (1949, 1952, 1968 & 1986) the collaboration rate was below 0.5. After 
1992, exponential growth in collaboration was observed till 2019 (CC=0.71); however, in 2020, a 
small dip in CC (0.68). The Collaboration Index (CI) provides the mean number of authors per paper 
for the study period (proposed by Lawani, 1980), i.e. an average number of authors per paper for a 
particular year. It considers the total number of authors, including single-author and the total number 
of papers to calculate.  The average number of authors per paper to the whole study period was 5.275. 
























1946 0 1 0 0 0 0 1 0.00 0 1.00 
1948 0 1 1 0 0 0 2 0.25 2 1.50 
1949 0 0 0 0 0 1 1 0.80 5 5.00 
1952 0 0 0 0 0 1 1 0.80 5 5.00 
1953 0 0 0 1 0 0 1 0.67 3 3.00 
1954 0 1 0 0 0 0 1 0.00 0 1.00 
1955 0 1 1 0 0 0 2 0.25 2 1.50 
1956 0 1 0 1 0 0 2 0.33 3 2.00 
1957 0 0 1 1 0 0 2 0.58 5 2.50 
1958 0 1 1 0 0 0 2 0.25 2 1.50 
1959 0 0 1 0 1 0 2 0.63 6 3.00 
1960 0 2 0 2 0 0 4 0.33 6 2.00 
1961 0 1 0 1 0 0 2 0.33 3 2.00 
1962 0 7 5 2 2 0 16 0.33 24 1.94 
1963 0 14 5 8 2 0 29 0.32 42 1.93 
1964 0 7 8 4 2 1 22 0.41 43 2.27 
1965 1 6 8 4 3 0 22 0.45 40 2.09 
1966 0 5 7 2 0 1 15 0.38 25 2.00 
1967 0 3 6 5 2 0 16 0.49 35 2.38 
1968 1 2 3 1 2 1 10 0.55 23 2.50 
1969 0 3 5 1 0 0 9 0.35 13 1.78 
1970 0 6 4 3 1 0 14 0.34 21 1.93 
1971 1 5 6 1 1 2 16 0.44 30 2.19 
1972 0 3 2 1 1 0 7 0.35 11 2.00 
1973 1 13 10 9 5 2 40 0.43 77 2.25 
1974 1 14 9 7 4 0 35 0.38 55 1.97 
1975 0 15 11 17 6 3 52 0.46 116 2.52 
1976 1 21 14 5 7 2 50 0.36 82 2.06 
1977 0 26 15 15 3 3 62 0.36 103 2.08 
1978 1 26 12 7 5 4 55 0.34 87 2.05 
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1979 0 34 9 17 5 4 69 0.33 111 2.10 
1980 1 30 22 13 12 6 84 0.41 166 2.33 
1981 2 27 16 16 8 4 73 0.41 137 2.25 
1982 0 45 26 19 12 6 108 0.37 188 2.16 
1983 3 38 27 15 11 7 101 0.40 189 2.25 
1984 2 37 19 16 10 11 95 0.40 188 2.37 
1985 4 40 18 30 14 10 116 0.44 244 2.45 
1986 4 24 33 26 8 16 111 0.51 266 2.61 
1987 2 18 26 15 10 7 78 0.49 177 2.50 
1988 1 26 18 17 7 24 93 0.49 254 3.01 
1989 1 30 28 10 16 11 96 0.44 214 2.54 
1990 3 49 17 15 15 18 117 0.40 248 2.54 
1991 3 50 41 27 18 39 178 0.48 494 3.06 
1992 6 49 52 30 21 39 197 0.50 537 2.97 
1993 2 68 49 36 38 63 256 0.51 750 3.20 
1994 4 56 48 47 32 72 259 0.54 816 3.37 
1995 12 57 79 28 29 73 278 0.54 858 3.29 
1996 5 56 61 32 40 68 262 0.54 853 3.47 
1997 4 51 49 27 18 55 204 0.51 624 3.31 
1998 3 63 53 48 25 51 243 0.50 688 3.09 
1999 4 70 63 43 29 78 287 0.52 924 3.46 
2000 5 69 58 43 33 97 305 0.54 1039 3.63 
2001 12 69 76 50 49 94 350 0.56 1144 3.47 
2002 8 99 88 69 66 130 460 0.55 1540 3.56 
2003 5 75 108 86 66 160 500 0.59 1985 4.12 
2004 10 98 131 89 72 171 571 0.57 2058 3.78 
2005 7 92 138 99 103 205 644 0.60 2465 3.97 
2006 6 111 150 115 96 256 734 0.59 2945 4.16 
2007 4 93 166 139 82 314 798 0.62 3349 4.31 
2008 6 114 157 136 121 313 847 0.61 3583 4.36 
2009 1 113 168 128 125 349 884 0.61 3993 4.64 
2010 4 88 165 138 128 361 884 0.64 4075 4.71 
2011 4 86 145 151 117 367 870 0.64 3962 4.65 
2012 6 86 166 167 140 396 961 0.65 4740 5.02 
2013 4 76 164 150 171 491 1056 0.67 5247 5.04 
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2014 4 49 148 139 120 466 926 0.68 5188 5.66 
2015 2 51 144 142 163 468 970 0.69 5474 5.70 
2016 2 58 131 168 155 538 1052 0.69 6199 5.95 
2017 0 46 139 178 179 656 1198 0.71 7352 6.18 
2018 7 48 134 176 195 721 1281 0.71 8472 6.65 
2019 6 50 153 181 216 755 1361 0.71 9033 6.67 













(42.76%) 26186  0.63  134840  5.27  
 
 
Form-wise distribution of publications  
 
 Hydroxychloroquine related publications have been published in a variety of bibliographic 
forms. Table 6 depicts the overall distribution of the publications by bibliographic forms as indexed in 
the Scopus database. Majority of the publications have been published in the form of journal articles 
(16,089) which constitute 61.44 percentage of the overall publications, followed by Reviews (5,291; 
20.21%) and Letters (2,504; 9.56%). The other details are presented in table 6.  
 






Journal Articles 16,089 61.44 
Reviews 5,291 20.21 
Letters 2,504 9.56 
Notes 718 2.74 
Editorials 570 2.18 
Conference Papers 454 1.73 
Short Surveys 442 1.69 
Book Chapters 75 0.29 
Erratums 30 0.11 
Data Paper 4 0.02 
Retracted 3 0.01 
Book 1 0.00 
Undefined 5 0.02 




Top twenty-five Productive Journals in the field of Hydroxychloroquine 
 
 The data in Table 6 indicates that out of 16,186 total publications, 16,089 publications found 
to be Journal articles. A total of 13,380 publications were published in 2,952 journals by the 
scientists/authors in Hydroxychloroquine. The Journal of Rheumatology found to be the most 
preferred avenue for the publications in Hydroxychloroquine, with 864 publications that received 
27,942 citations, followed by Lupus published 782 publications (SAGE publisher) and Annals of the 
Rheumatic Diseases published 519 publications (by BMJ Publishing Group). Out of the top twenty-
five journals, 10 Journals are being published from the United States of America, followed by eight 
journals from the United Kingdom. Among the top twenty-five journals, the journal Annals of the 
Rheumatic Diseases has the highest Impact Factor (IF) (14.299) published by BMJ Publishing Group, 
United Kingdom, followed by the journal Arthritis and Rheumatism (9.002) published by Wiley-
Blackwell, USA. Six publications were published by Elsevier, followed by four publications by 
Wiley-Backwell both from the USA. The journal BMJ Case Reports do not have an Impact Factor 
since case studies are rarely cited. Out of twenty-five highly productive journals, seven are being 
published by Wiley-Blackwell and five are by Elsevier. 
 










Journal Of Rheumatology 3.634 
Journal of 
Rheumatology 
Publishing Co., Ltd. Canada 864 27942 
Lupus 2.924 SAGE UK 782 14664 
Annals Of The Rheumatic Diseases 14.299 BMJ Publishing Group UK 519 34531 
Clinical Rheumatology 2.293 Springer Nature UK 466 6520 
Clinical And Experimental 
Rheumatology 3.238 Pacini Editore SpA Italy 417 8252 
Rheumatology 5.149 
Oxford University 
Press UK 311 15335 
Arthritis And Rheumatism 9.002 Wiley-Blackwell USA 304 42869 
Journal Of The American Academy 
Of Dermatology 7.102 Elsevier USA 298 11062 
Rheumatology International 2.2 Springer Nature Germany 296 3258 
Journal Of Clinical Rheumatology 1.897 Future Medicine Ltd. USA 275 2483 
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Arthritis Care And Research 4.53 Wiley-Blackwell Wiley 266 12607 
Seminars In Arthritis And 
Rheumatism 5.072 Elsevier USA 210 8513 
Arthritis Research And Therapy 4.148 Springer Nature UK 168 5880 
BMJ Case Reports #N/A BMJ Publishing Group UK 167 399 
Scandinavian Journal Of 
Rheumatology 2.706 Taylor & Francis Norway 165 2980 
Archives Of Dermatology 7.995 
American Medical 
Association USA 156 6741 
Current Opinion In Rheumatology 3.851 Wolters Kluwer Health USA 152 2587 
British Journal Of Dermatology 6.714 Wiley-Blackwell UK 144 4594 
Dermatologic Therapy 1.74 Wiley-Blackwell USA 144 1163 
Autoimmunity Reviews 7.716 Elsevier USA 142 4962 
Joint Bone Spine 3.278 Elsevier France 139 1855 
International Journal Of 
Dermatology 1.794 Wiley-Blackwell USA 138 3570 
Clinical And Experimental 
Dermatology 1.771 Wiley-Blackwell UK 137 1729 
International Journal Of Rheumatic 
Diseases 1.938 Wiley-Blackwell Australia 136 1127 
Rheumatic Disease Clinics Of North 
America 3.527 Elsevier USA 125 3358 
 
Top twenty-five most fruitful authors in the field of Hydroxychloroquine 
 
 A total of 88,834 unique authors (Overall 1,37,974 authors, including multiple papers) 
contributed 26,186 papers. Table 8 depicts the top twenty-five most fruitful authors in the field of 
Hydroxychloroquine. Among the top twenty-five authors, Didier A. Raoult from Aix Marseille 
University, Marseille of France has published 131 papers with 9,004 citations to his credit, followed 
by Michelle A. Petri from Johns Hopkins School of Medicine, Baltimore of USA with 109 
publications (6,901 citations) and Jean Charles Piette of AP-HP Assistance Publique-Hopitaux de 
Paris, France with 96 publications (4,333 citations) ranked first to third respectively. Among the top 
twenty-five authors, nine authors belong to the USA, followed by six authors belong to France. 
Though the author Maxime R. Dougados ranked nineteenth but received the highest citations, i.e. 
10,170 (highest ACPP with 172.37), Paul D. Emery followed 9,715 citations (with highest 140.80 
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ACPP) ranked second. Didier A. Raoult and Michelle A. Petri have the highest h-index (43), followed 
by Munther A. Khamshta with 40 h-index among the top twenty-five most productive authors in the 
field of Hydroxychloroquine.  
 
Table 8: Top twenty-five productive authors in the field of Hydroxychloroquine 
 
Name of Author Affiliation Country TP TC ACPP h-index 
Didier A. Raoult Aix Marseille University, Marseille France 131 9004 68.73 43 
Michelle A. Petri 
Johns Hopkins School of Medicine, 
Baltimore 
USA 109 6901 63.31 43 
Jean Charles Piette 
AP-HP Assistance Publique - 
Hopitaux de Paris, Paris 
France 96 4333 45.14 37 
Zahir Amoura 
Hôpital Universitaire Pitié Salpêtrière, 
Paris 
France 87 4103 47.16 35 
Munther A. 
Khamashta 
Guy's and St Thomas' NHS 
Foundation Trust, London 
UK 85 6706 78.89 40 
Nathalie CostéDoat-
Chalumeau 
Hopital Cochin AP-HP, Paris France 85 3506 41.25 33 
Angela A. Tincani 
Università degli Studi di Brescia, 
Brescia 
Italy 78 3892 49.90 33 
Hannu J. Kautiainen Folkhälsan, Helsinki Finland 72 3418 47.47 25 
Yehuda Shoenfeld 
Chaim Sheba Medical Center Israel, 
Tel Aviv-Yafo 
Israel 70 4173 59.61 35 
Paul D. Emery University of Leeds, Leeds UK 69 9715 140.80 31 
Tom W.J. Huizinga 
Leiden University Medical Center - 
LUMC, Leiden 
Netherlands 67 6224 92.90 30 
Victoria P. Werth VA Medical Center USA 66 1813 27.47 23 
James R. O'Dell 
University of Nebraska Medical 
Center, Omaha 
USA 65 7569 116.45 25 
Jeffrey P. Callen 
University of Louisville Health 
Sciences Center, Louisville 
USA 63 2431 38.59 25 
Daniel J. Wallace 
Cedars-Sinai Medical Center, Los 
Angeles 
USA 63 4027 63.92 28 
Tuulikki M. Sokka Jyvaskyla Central Hospital, Jyvaskyla Finland 62 4135 66.69 31 





Helsingin Yliopisto, Helsinki Finland 60 3166 52.77 25 
Maxime R. Dougados Universite Paris-Saclay, Saint-Aubin France 59 10170 172.37 28 
Jeffrey R Curtis University of Alabama at Birmingham USA 58 5017 86.50 29 
Olivier Fain Sorbonne Universite, Paris France 57 1697 29.77 23 
Eric L. Matteson Mayo Clinic, Rochester USA 56 4076 72.79 28 
Theodore P. Pincus 
Rush University Medical Center, 
Chicago 
USA 56 3434 61.32 29 
Bernardus A.C. 
Dijkmans 
Amsterdam UMC - Vrije Universiteit 
Amsterdam, Amsterdam 
Netherlands 54 3935 72.87 31 
Guillermo Ruiz-
Irastorza 
Osakidetza, Cruces University 
Hospital, Baracaldo 
Spain 53 3480 65.66 22 
(TP-Total Publications; TC-Total Citations and ACPP-Average Citations per Paper) 
 
Top twenty-five prolific institutions 
 
 Table 9 indicates the top twenty-five most prolific institutions in the field of 
Hydroxychloroquine. Out of top twenty-five most prolific institutions, AP-HP Assistance Publique-
Hopitaux de Paris has published the highest papers, i.e. 465, followed by Institut national de la santé 
et de la recherche médicale (Inserm), Paris with 464, Harvard Medical School with 385 publications 
ranked first to third respectively. Among the listed institutes Harvard Medical School has received 
highest 20,115 citations, followed by Inserm (16931) and Brigham and Women's Hospital (16847). 
Ranking list according to h-index by top-25 institutes is topped by Harvard Medical School (64) 
followed by Inserm (63) and AP-HP Assistance Publique - Hopitaux de Paris (62) respectively.  
 
Out of the top twenty-five institutions, six institutions are based in Paris alone, followed by two 
institutions based at Boston, Birmingham, London, and New York. Among the country affiliation, 13 
institutions belong to the USA, whereas six institutions belong to France and two from the 
Netherlands and the United Kingdom.  
 
Table 9: Top twenty-five prolific institutions 






AP-HP Assistance Publique - Hopitaux 
de Paris Paris France 465 15045 62 
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Inserm Paris France 464 16931 63 
Harvard Medical School Boston USA 385 20115 64 
Brigham and Women's Hospital Boston USA 335 16847 60 
University of Toronto Toronto Canada 300 12198 56 
Mayo Clinic Rochester USA 288 13856 56 
Université de Paris Paris France 266 13639 53 
Hôpital Universitaire Pitié Salpêtrière Paris France 259 9790 53 
Sorbonne Universite Paris France 229 7433 42 
University of California 
San 
Francisco USA 224 11986 50 
University of Pennsylvania Philadelphia USA 220 10446 51 
University College London London 
United 
Kingdom 218 11188 54 
VA Medical Center Washington USA 213 6971 44 
Hospital Cochin AP-HP Paris France 211 12239 51 
Johns Hopkins School of Medicine Baltimore USA 210 8839 50 
Università degli Studi di Milano Milan Italy 208 5653 40 
The University of Alabama at 
Birmingham Birmingham USA 204 11231 54 
Leiden University Medical Center - 
LUMC Leiden Netherlands 189 15861 58 
Weill Cornell Medicine New York USA 188 7564 41 
Università degli Studi di Roma La 
Sapienza Rome Italy 178 5713 34 
Aix Marseille Université Marseille France 178 8725 45 
Charité – Universitätsmedizin Berlin Berlin Germany 175 12501 51 
Cleveland Clinic Foundation Cleveland USA 173 5231 35 
Massachusetts General Hospital Boston USA 170 8635 42 
Hospital Clinic Barcelona Barcelona Spain 168 7232 43 
 
 
Distribution of top twenty-five Publications by Country wise 
 
 Table 10 presents the data on the country-wise distribution of publications. Totally there were 
159 countries contributed to Hydroxychloroquine research field. Among the top twenty-five countries, 
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the United States of America has published the highest publications, i.e. 8,490 (the USA alone has 
contributed 32.42% of the total publications), followed by France with 2152 publications (8.22%), the 
United Kingdom with 2146 (8.20%) publications ranked first to third respectively. The top twenty-
five counties contributed nearly 85% of the total publications, whereas 134 countries contributed 4077 
(15.57%) publications.  
 
Table 10: Distribution of top twenty-five Publications by Country wise 









United States 8490 32.42 South Korea 504 1.92 
France 2152 8.22 Switzerland 429 1.64 
United Kingdom 2146 8.20 Taiwan 422 1.61 
Italy 1928 7.36 Iran 412 1.57 
India 1203 4.59 Israel 398 1.52 
Germany 1175 4.49 Greece 346 1.32 
Canada 1108 4.23 Belgium 322 1.23 
Spain 1072 4.09 Sweden 305 1.16 
China 1040 3.97 Finland 279 1.07 
Netherlands 870 3.32 Japan 241 0.92 
Australia 770 2.94 Egypt 209 0.80 
Turkey 655 2.50 Portugal 205 0.78 
Brazil 514 1.96 134 Countries 4077 15.57 
 
 
Mapping of Keyword Co-occurrence 
 
The map was constructed using VOSviewer visualization software, and the required data was 
extracted from the Scopus citation database. The Keyword co-occurrence map visualises the terms 
which have appeared at least 2000 times as keyword in all documents included. There are three 
clusters in the above map with 73 keywords and 2612 links. The links between two keywords in the 
network show number of times the keywords linked appeared together in the publications. Higher the 
number of links between two keywords, higher the number of times they have co-occurred in the 
documents. The network based on keywords determines the nature of research and research hotspots 
in the area of Hydroxychloroquine (HCQ). The keywords (male and female, and adults, child, 
adolescents, middle-aged, aged etc.) indicate that HCQ drug research was based on gender and age 
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criteria. Controlled and clinical studies were frequently used in research methods. The keywords like 
"Covid-19", "Coronavirus disease 2019", "Coronavirus infections", "betacoronavirus", "pandemic" 
have prominently placed in these highly used keywords and created a separate cluster, in blue colour, 
due to recent drug repurposing experiments and case studies of Hydroxychloroquine in the treatment 
for COVID-19 in 2020. The safety and efficacy of drug HCQ in the treatment of diseases such as 
"rheumatoid arthritis" and "Systemic lupus erythematosus (SLE)" were also found to be the prominent 
research area.  
 
Figure 4: Mapping of Keyword Co-occurrence 
 
 
Top five highly cited publications 
 
 The table 11 depicts the top five highly cited publications in the field of Hydroxychloroquine. 
18 articles have received more than 1000 citations. The article titled, "Hydroxychloroquine and 
azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" by 
Gautret P. et al.  (total 18 authors) published online since 20 March 2020 in International Journal of 
Antimicrobial Agents have received the highest 1864 citations in a years' time, whereas, the paper 
entitled, "Rheumatoid arthritis" by Scott, D.L.; Wolfe, F. and Huizinga, T.W.J. published in The 




Table 11: Top five highly cited publications in the field of Hydroxychloroquine 





Hydroxychloroquine and azithromycin as 
a treatment of COVID-19: results of an 
open-label non-randomized clinical trial Gautret P. et al.  18 
2020, International Journal 
of Antimicrobial Agents, 56 
(1): 105949 1864 
Rheumatoid arthritis 
Scott, D.L.; 
Wolfe, F. and 
Huizinga, 
T.W.J. 3 
2010, The Lancet 376 
(9746), pp. 1094-1108 1788 
Guidelines on the prevention, diagnosis, 
and treatment of infective endocarditis 
(new version 2009) Habib G. et al.  56 
2009, European Heart 
Journal 30 (19), pp. 2369-
2413 1489 
Interferon-inducible gene expression 
signature in peripheral blood cells of 
patients with severe Lupus 
Baechler E.C.et 
al.  12 
2003, Proceedings of the 
National Academy of 
Sciences of the United 
States of America 100 (5), 
pp. 2610-2615 1497 
Mechanisms of disease: Systemic lupus 
erythematosus Tsokos G.C. 1 
2011, New England 
Journal of Medicine 365 
(22), pp. 2110-2121 1357 
 
 
Findings and Conclusion 
 
The recent pandemic, COVID-19, is a threat to the whole of humankind. COVID-19 seems to 
be the most dangerous virus among the Coronavirus family. Until November 2020, there was no 
proper vaccine to treat COVID-19. In the process to find the right vaccine, the part of scientist and 
researcher community also worked on 'drug repurposing', Hydroxychloroquine which was used for 
the treatment of Malaria is being clinically tested as the prospective drug. Thousands of researchers 
have published their research works on Hydroxychloroquine in the form of journal articles, 
conference papers, case studies, commentary, lab trails, book chapters, notes, surveys etc. Which has 
resulted in 22.8% overall publication on 'Hydroxychloroquine' has published in the year 2020 only. 
This study presents the published literature on 'Hydroxychloroquine' and its clinical evidence to 
evaluate the safety and effectiveness of the treatment of COVID-19. It also analysed the research 




 Out of 26,186 publications, 10,463 (39.9%) papers were published as open access and 
received 2,77,404 (48.87%) of the total citations. A fluctuating trend was observed for AGR, and the 
value of the Compound Annual Growth Rate (CAGR) for the total period of study was 0.129635. The 
maximum RGR 0.56 recorded in the year 1963 and minimum of 0.04 in the year 1972. The maximum 
19.35 doubling time was recorded in 1972, and minimum 1.26 doubling time was recorded in 1948, 
the recent lowest doubling time is 2.80 recorded for the publications in the year 2020. Many multi-
authored publications dominate over the single authored publications with a 0.88 Degree of 
Collaboration and 5.27 Collaborative Index. The Journal of Rheumatology was the most preferred 
avenue to publish the research papers. The journal Annals of the Rheumatic Diseases has the highest, 
i.e. 14.299 Impact Factored among the top twenty-five journals. Although Didier A. Raoult of Aix 
Marseille University was the most productive author (131 publications), Maxime R. Dougados of the 
Universite Paris-Saclay, Saint-Aubin received the maximum number of citations and the highest 
average citations per paper among the other authors. AP-HP Assistance Publique - Hopitaux de Paris 
was the most productive institute with the maximum number of publications, and Harvard Medical 
School of Boston received the maximum number of citations. The United States of America was the 
most productive country among the 159 countries contributed. The study concludes that there has 
been a consistent trend towards increased literature in 'Hydroxychloroquine' in general. In particular, 
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